1Marcellin P, Chang Tr, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chron- ic hepatitis B. Hepatology ,2008 ,g8:750-758.
2Tavakoli S, Schwerin W, Rohwer A, et al. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. Gen Viro1,2004,85:2829-2836.
3Beckebaum S, Cicinnati VR,Zhang X, et al. Hepatitis B virus-induced defent of m0nocytederived dendritic cells leads to impaired T helper type 1 response In vitro:mechanisms for viral immune escape. Immunology, 2003,109:487-495.
4Akbar SM, Horlike N, Onji M, et al. Dendritic cells and chronic hepatitis virus carriers. Intervirology,2001,44 : 199-208.
5Schiff ER. Prevention of mortality form hepatitis B and hepatitis C. Lancet, 2006,368 : 896-897.
6Perz JF, Amstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepato1,2006,45:529-538.
7Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV infected patients. J Hepato1,2006,44 : $90-$94.
8Patrick M, Ting-Tsung C, Seng GL, et al. Adefovir dipivoxil for the treat- ment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003,348 : 808 -816.
9Schiffe, Laicl, Hadziyanniss, et al. Adefovir. dipivoxil forwait-listed and post-liver transplantation patients with lamivudine-risistant hepatitis B: Final long-term restlts. Liver Transp1,2007,13:349-360.
10Rappti I, Dmou E, Mitsoula P, et, ak Adding-on versus switching-to ade- fovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology,2007 ,45 :307-313.
6Shimizu Y, Guidotti LG, Fowler P, et al. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol, 1998, 161: 4520-4529.
7Ponsaerts P, Van den Bosch G, Cools N, et al. Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol,2002,169: 1669-1675.
8Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (Poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol, 1999,163: 57-61.
9Lechmann M, Berchtold S, Hauber J, et al. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol, 2002,23: 273-275.
10Akbar SM, Horiike N, Onji M, et al. Dendritic cells and chronic hepatitis virus carriers. Intervirology, 2001, 44: 199-208.
